Evaluation of the Safety of Palivizumab in the Second Season of Exposure in Young Children at Risk for Severe Respiratory Syncytial Virus Infection

Author： Lacaze-Masmonteil T.  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.26, Iss.4, 2003-01, pp. : 283-291

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children: A UK Analysis

By Nuijten Mark J.C.   Wittenberg Wolfgang   Lebmeier Maximilian  

PharmacoEconomics, Vol. 25, Iss. 1, 2007-01 ,pp. : 55-71

Adis International

Access to resources Recommend Favorite

Palivizumab: A Review of its Use as Prophylaxis for Serious Respiratory Syncytial Virus Infection

By Fenton Caroline   Scott Lesley J.   Plosker Greg L.  

Pediatric Drugs, Vol. 6, Iss. 3, 2004-01 ,pp. : 177-197

Adis International

Access to resources Recommend Favorite

Emerging drugs for respiratory syncytial virus infection

By Olszewska Wieslawa   Openshaw Peter  

Expert Opinion on Emerging Drugs, Vol. 14, Iss. 2, 2009-06 ,pp. : 207-217

Informa Healthcare

Access to resources Recommend Favorite

Respiratory Syncytial Virus Infection in Elderly Adults

By Falsey Ann R.   Walsh Edward E.  

Drugs & Aging, Vol. 22, Iss. 7, 2005-01 ,pp. : 577-587

Adis International

Access to resources Recommend Favorite

Respiratory Syncytial Virus Infection in Adult Populations

By  

Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 12, Iss. 2, 2012-04 ,pp. : 98-102

Bentham Science Publishers

Access to resources Recommend Favorite